Novartis Shares Climb as FDA Designates Ianalumab as Breakthrough Therapy

Shares of Novartis (NVS) experienced a 1% increase on Friday following the announcement from the U.S. Food and Drug Administration (FDA) that it has granted breakthrough therapy designation to the company’s drug, Ianalumab. This designation is aimed at facilitating the development and review of therapies addressing serious conditions.

The breakthrough therapy designation is particularly significant for Novartis as it seeks to position Ianalumab as a potential first-line treatment for Sjögren’s disease, a chronic autoimmune disorder. The company plans to submit data from its extensive trials to health authorities beginning in early 2026, with hopes of gaining regulatory approval.

Understanding Sjögren’s Disease

Sjögren’s disease affects the body’s exocrine glands, leading to widespread inflammation and tissue damage. Over 90% of patients experience symptoms such as dry eyes and dry mouth, significantly impacting their quality of life. Currently, there are limited treatment options available, underscoring the importance of Ianalumab’s potential introduction to the market.

The breakthrough therapy designation aims to expedite the review process for medications that address serious or life-threatening conditions. This designation reflects the FDA’s commitment to accelerating patient access to promising new therapies.

If approved, Ianalumab could mark a significant advancement in the management of Sjögren’s disease, offering hope to the thousands affected by this condition. As Novartis moves forward with its submission plans, updates will be closely monitored by investors and healthcare professionals alike.